Ose Pharma Sa Stock Debt To Equity
| OSE Stock | EUR 7.80 0.41 4.99% |
OSE Pharma SA fundamentals help investors to digest information that contributes to OSE Pharma's financial success or failures. It also enables traders to predict the movement of OSE Stock. The fundamental analysis module provides a way to measure OSE Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OSE Pharma stock.
OSE |
OSE Pharma SA Company Debt To Equity Analysis
OSE Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current OSE Pharma Debt To Equity | 7.20 % |
Most of OSE Pharma's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, OSE Pharma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, OSE Pharma SA has a Debt To Equity of 7.2%. This is 86.55% lower than that of the Biotechnology sector and 62.81% lower than that of the Health Care industry. The debt to equity for all France stocks is 85.22% higher than that of the company.
OSE Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses OSE Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of OSE Pharma could also be used in its relative valuation, which is a method of valuing OSE Pharma by comparing valuation metrics of similar companies.OSE Pharma is currently under evaluation in debt to equity category among its peers.
OSE Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0528 | |||
| Profit Margin | (0.22) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 128.18 M | |||
| Shares Outstanding | 18.44 M | |||
| Shares Owned By Insiders | 39.03 % | |||
| Shares Owned By Institutions | 1.81 % | |||
| Price To Earning | 10.60 X | |||
| Price To Book | 2.64 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 26.31 M | |||
| Gross Profit | 26.31 M | |||
| EBITDA | (13.72 M) | |||
| Net Income | (16.85 M) | |||
| Cash And Equivalents | 33.58 M | |||
| Cash Per Share | 0.84 X | |||
| Total Debt | 34.77 M | |||
| Debt To Equity | 7.20 % | |||
| Current Ratio | 2.54 X | |||
| Book Value Per Share | 2.53 X | |||
| Cash Flow From Operations | (9.92 M) | |||
| Earnings Per Share | (0.41) X | |||
| Target Price | 14.1 | |||
| Number Of Employees | 60 | |||
| Beta | 1.06 | |||
| Market Capitalization | 104.49 M | |||
| Total Asset | 101.88 M | |||
| Retained Earnings | 25 M | |||
| Working Capital | 22 M | |||
| Current Asset | 30 M | |||
| Current Liabilities | 8 M | |||
| Z Score | 1.8 | |||
| Net Asset | 101.88 M |
About OSE Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OSE Pharma SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OSE Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OSE Pharma SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in OSE Stock
OSE Pharma financial ratios help investors to determine whether OSE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OSE with respect to the benefits of owning OSE Pharma security.